Fig. 6From: Recent advances and limitations of mTOR inhibitors in the treatment of cancerGeneration of RapaLinks. Linking an mTOR kinase inhibitor INK-128 (or MLN0128) to rapamycin led to RapaLinks which exhibited improved efficacy in tumor-bearing mice than each of the constituents aloneBack to article page